louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06821022: The Impact of Pain Neuroscience Education on Physical Therapy Student's Knowledge, Attitudes, Beliefs, and Behaviours Towards Pain
Official title: The Impact of Pain Neuroscience Education on Physical Therapy Student's Knowledge, Attitudes, Beliefs, and Behaviours Towards Pain
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Healthy Subjects
Keywords: Pain
Physiotherapy students
Attitudes
Education
Lead sponsor: The Hashemite University
Sponsor class: OTHER
First posted: 2025-02-11
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This study investigates the effect of pain neuroscience education (PNE) on pain knowledge, attitudes, and beliefs among undergraduate physiotherapy students in Jordan

Detailed description: Physiotherapy students at the Hashemite University will be randomly assigned into either pain neuroscience education or control lectures groups. Both groups will receive a 70-min didactic group-lecture. The control group will receive education about red-flags which are special screening questions for serious pathology. The red-flags education will discuss tissue pathology and triage for back pain classification. Neurophysiology and the biopsychosocial mode will not be discussed. The intervention group will receive a PNE lecture

Eligibility criteria: Inclusion Criteria:

* Physiotherapy undergraduate students at the Hashemite University

Exclusion Criteria:

* Previous formal pain education
* Enrolled in a clinical practice module

Primary outcomes:
measure: Revised Pain Neurophysiology Questionnaire (RNPQ)
timeFrame: Before and immediately after the education session
measure: The modified HC-PAIRS
timeFrame: Prior to and immediately after the education session
Secondary outcomes:
measure: Case vignette to measure behaviour (clinical recommendations).
timeFrame: Before and immediately after the education session
Other outcomes:
Locations:
city: Zarqa
country: Jordan
facility: The Hashemite University
Study officials:
References:
citation: Colleary G, O'Sullivan K, Griffin D, Ryan CG, Martin DJ. Effect of pain neurophysiology education on physiotherapy students' understanding of chronic pain, clinical recommendations and attitudes towards people with chronic pain: a randomised controlled trial. Physiotherapy. 2017 Dec;103(4):423-429. doi: 10.1016/j.physio.2017.01.006. Epub 2017 Mar 22.
Clinical trial NCT01549522: Qualitative Research for Stage 4 Liver Cancer Patients and Their Caregivers
Official title: Phase 1 0 Qualitative Research for Stage 4 Liver Cancer Patients and Their Caregivers.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Stage 4 Liver Cancer
Keywords: patients or caregivers
for caregivers, loved one must still be living
Lead sponsor: Find A Cure Panel
Sponsor class: OTHER
First posted: 2012-03-09
Enrollment: 30
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: liver cancer stage 4 patients and caregivers

Brief summary: This is opinion based, experiential research and is NOT a drug trial.


Eligibility criteria: Inclusion Criteria:

* stage 4 liver cancer patients and caregivers

Exclusion Criteria:

* loved ones passed away

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: National
state: California
Study officials:
References:
Clinical trial NCT00326222: Patient Education in NorthTrondelag Hospital Trust
Official title: Patient Education in NorthTrondelag Hospital Trust - Interventions, Effects and Patient Experience
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus
Keywords: Patient Education as a Topic
Self-Management Program
Health promotion
Self Efficacy
Quality of life
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
Collaborators: name: Helse Nord-Trøndelag HF
First posted: 2006-05-16
Enrollment: 146
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: The purpose of this randomised open study is to examine the effect of self-management program for diabetes patients.

Detailed description: The primary aim in this study is HbA1c in addition to secondary aims like quality of life and coping.

Eligibility criteria: Inclusion Criteria:

* Diagnosed with ICPC-2, code T89 - diabetes dependent on insulin and T90 diabetes not dependent on insulin

Exclusion Criteria:

* Diagnosed with ICPC-2, code T89 - diabetes mellitus juvenile and diabetes I
* Attended self-management program previous 12 months

Primary outcomes:
measure: HbA1c
timeFrame: Baseline, 6, and 12 mds
measure: PAM - Patient activation measure
timeFrame: Baseline, 6, and 12 mds
Secondary outcomes:
measure: SF36
timeFrame: Baseline, 6, and 12 mds
measure: EQ 5D-VAS scale
timeFrame: Baseline, 6, and 12 mds
measure: Hunt diabetes
timeFrame: Baseline, 6, and 12 mds
measure: WHO-DTSQ
timeFrame: Baseline, 6, and 12 mds
measure: Knowledge of diabetes
timeFrame: Baseline, 6, and 12 mds
measure: HDL-cholesterol
timeFrame: Baseline, 6, and 12 mds
measure: Total cholesterol
timeFrame: Baseline, 6, and 12 mds
measure: Creatinin
timeFrame: Baseline, 6, and 12 mds
measure: Blood pressure
timeFrame: Baseline, 6, and 12 mds
measure: Weight
timeFrame: Baseline, 6, and 12 mds
measure: BMI
timeFrame: Baseline, 6, and 12 mds
measure: Cost/benefit
timeFrame: Baseline, 6, and 12 mds
measure: Triglyceride
timeFrame: Baseline, 6, and 12 mds
Other outcomes:
Locations:
city: Levanger
country: Norway
facility: Nord-Trondelag Hospital Trust
state: Nord-Trondelag
Study officials:
affiliation: Norwegian University of Science and Technology, Trondheim, Norway
name: Aslak Steinsbekk, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Norwegian University of Science and Technology
name: Lisbeth O Rygg, Master
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rygg LO, Rise MB, Gronning K, Steinsbekk A. Efficacy of ongoing group based diabetes self-management education for patients with type 2 diabetes mellitus. A randomised controlled trial. Patient Educ Couns. 2012 Jan;86(1):98-105. doi: 10.1016/j.pec.2011.04.008. Epub 2011 May 17.
Clinical trial NCT03668522: Clinical Research of H3F3AK27M in Spinal Glioma and Its Impact on TMZ Chemoradiotherapy
Official title: Clinical Research of the Molecular Phenotype Distribution of H3F3AK27M in Spinal Glioma and Its Impact on TMZ Chemoradiotherapy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Spinal Tumor
Keywords: H3F3AK27M
Lead sponsor: Southern Medical University, China
Sponsor class: OTHER
First posted: 2018-09-12
Enrollment: 60
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Surgical treatment and pathological confirmation of spinal glioma in our department.

Brief summary: H3F3AK27M may be a feature of primary spinal cord glioma and affect the outcome and prognosis of TMZ chemoradiotherapy.


Eligibility criteria: Inclusion Criteria:

* Surgical treatment and pathological confirmation of spinal glioma in our department and is the first case without any treatment before operation.

Exclusion Criteria:

* The tumor is recurrent or has been treated before operation.

Primary outcomes:
measure: positive
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Nan fang hospital, Southern medical university
state: Guangdong
Study officials:
affiliation: Nanfang Hospital Neurosurgery Department
name: Lu Yuntao, M.D., Ph.D
role: STUDY_CHAIR
References:
Clinical trial NCT03285022: Postoperative Hypersensitivity and Digital Radiographic Assessment of a Zinc Modified Versus a Conventional Glass Ionomer Cement in Deep Carious Lesion: Randomized Controlled Clinical Trial
Official title: Postoperative Hypersensitivity and Digital Radiographic Assessment of a Zinc Modified Versus a Conventional Glass Ionomer Cement in Deep Carious Lesion: Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Carious Dentin
Keywords: Incomplete caries removel
Partial caries removel
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-09-15
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The study aim to evaluate the difference between the effect of zinc modified glass ionomer and conventional glass ionomer on the success of partial caries removel technique

Detailed description: The zinc ion has an antibacterial effect which could increase the success of partial caries removel technique by decreasing the bactrial population .

Eligibility criteria: Inclusion Criteria:

1. Male or female (\>18 y)
2. patient with At least 1 deep carious lesion
3. Clinical symptoms of reversible pulpitis with positive pulp response

Exclusion Criteria:

* 1. Patient suffer from irreversible pulpitis (pain with hot or instant pain lasting for a while, resistant to analgesic) 2. Presence of any sign of periapical lesion (like sinus tract ) 3. Teeth with periodontal problem 4. Anterior teeth (material used for non aesthetic region) 5. Pregnant women, to avoid multiple exposure to x ray 6. Patients unable to give consent(mentally retarted, or refuse to right a consent)

Primary outcomes:
measure: Digital radigraphic assessment
timeFrame: At baseline ,3months and 6 months
Secondary outcomes:
measure: Post opreative hypersenstivity
timeFrame: Baseline ,at 3 months and at 6 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05656222: Irinotecan and Anlotinib for Epithelioid Sarcoma
Official title: A Retrospective Study Investigating the Combination of Irinotecan, Vincristine and Anlotinib for Epithelioid Sarcoma
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Objective Response
Overall Survival
Keywords: Epithelioid sarcoma
systemic treatment
objective response
toxicity
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2022-12-19
Enrollment: 0
Sex: ALL
Minimum age (years): 3
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Epithelioid sarcoma is a rare soft tissue sarcoma characterized by SMARCB1/INI1 deficiency. Much attention has been paid to the selective EZH2 inhibitor tazemetostat, where other systemic treatments are generally ignored. To explore alternative treatment options, we studied the effects of irinotecan-based chemotherapy in a series of epithelioid sarcoma patients.


Eligibility criteria: Inclusion Criteria:

* (1) Grade 2 or 3 ES confirmed histologically using the American Joint Committee on Cancer (AJCC) system ;
* (2) patients presented with measurable lesions using the Response Evaluation Criteria In Solid Tumors (RECIST1.1) and were not amenable to surgical resection or radiotherapy;
* (3) primary or secondary metastatic disease;
* (4) received more than two courses of the VIA regimen;
* (5) no concurrent treatment was given while on the VIA regimen;
* (6) follow-up information and evaluation after chemotherapy were available.

Exclusion Criteria:

* less than 4 cycles of treatment;
* medical records were not complete.

Primary outcomes:
measure: Objective Response Rate
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University People's Hospital
Study officials:
References:
Clinical trial NCT03810222: A Prospective Outcome Study in Patients With Moderate to Severe Traumatic Brain Injury
Official title: A Prospective Outcome Study in Patients With Moderate to Severe Traumatic Brain Injury in Bergamo Area (Italy)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Brain Injuries, Traumatic
Brain Injury Traumatic Moderate
Brain Injury Traumatic Severe
Keywords: TBI moderate, TBI severe, GOSE
Lead sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Sponsor class: OTHER
First posted: 2019-01-18
Enrollment: 225
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients admitted to the ICU with a diagnosis of moderate (Glasgow Coma Scale, GCS 9-13) or severe TBI (GCS 3-8), with or without associated polytrauma. Patients transferred from other hospitals within the first 24h are included.

Brief summary: Traumatic brain injury (TBI) is the leading cause of death, disability and cognitive impairment in young people worldwide. The majority of the traumatic deaths in developed countries results directly from lesions in the central nervous system. Furthermore, due to the persistence of disabling effects of TBI for many years, personal and public costs of supporting survivors have to be taken in consideration.

Many patients rescued by ICU treatment may have been severely disabled or vegetative because of trauma. These data suggest that, despite improvement in medical and surgical treatments, other factors related to trauma itself and to patient's condition could have an impact on the final outcome.

Aim of the TBI-PRO project is to collect high quality clinical and epidemiological data and to describe the outcome of moderate-to-severe TBI in a local contest (Bergamo area, Italy).

Detailed description: All patients admitted to the ICU with a diagnosis of moderate-to-severe TBI, with or without polytrauma, are recruited. Bergamo hospital is the main Trauma Centre (Level I) and the only referring neurosurgical center within a population of 1.2 million inhabitants of Bergamo area. This hospital is also a Regional Pediatric Trauma Centre.

Eligibility criteria: Inclusion Criteria:

* admission to ICU
* diagnosis of moderate-to-severe TBI

Exclusion Criteria:

Patients who died in the first couple of hours after hospital admission are not included.

Primary outcomes:
measure: Glasgow Outcome Scale - Extended (GOSE)
timeFrame: 12 Months Post-Injury
Secondary outcomes:
measure: 6-Month Outcome
timeFrame: 6 Months Post-Injury
measure: Neuropsychological evaluation
timeFrame: 12 Months Post-Injury
Other outcomes:
Locations:
city: Bergamo
country: Italy
facility: ASST- Papa Giovanni XXIII
Study officials:
affiliation: ASST- Papa Giovanni XXIII
name: PAOLO GRITTI, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Fondazione per la Ricerca Ospedale di Bergamo (FROM)
name: FRANCESCO BIROLI, MD
role: STUDY_CHAIR
References:
Clinical trial NCT03844022: MRI in McArdle Disease (GSDV)
Official title: MRI in McArdle Disease (Glycogen Storage Disease Type V)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glycogen Storage Disease Type V
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2019-02-18
Enrollment: 87
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: McArdle disease (GSDV) Healthy controls

Brief summary: The aim of this study is to describe the degree of muscle wasting in patients with McArdle disease judged by MRI, quantitative magnetic resonance (DIXON) and T1 weighted images, and muscle strength, collected across multiple European sites and compared to healthy controls.


Eligibility criteria: Inclusion Criteria:

* GSDV or healthy controls

Exclusion Criteria:

* MRI contradictions

Primary outcomes:
measure: DIXON MRI
timeFrame: 1 time
Secondary outcomes:
measure: Muscle strength
timeFrame: 1 time
measure: T1 MRI
timeFrame: 1 time
measure: Back pain questionnaire
timeFrame: 1 time
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Copenhagen Neuromuscular Center, Rigshospitalet
Study officials:
References:
Clinical trial NCT04079322: Iron Absorption and Exercise
Official title: Fractional Iron Absorption in Response to an Acute Bout of Exercise
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Iron-deficiency
Iron Deficiency Anemia
Lead sponsor: Florida State University
Sponsor class: OTHER
First posted: 2019-09-06
Enrollment: 31
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Iron is a nutritionally essential mineral required for optimal physical and cognitive performance. Endurance exercise often leads to declines in iron status; however, the reason for the decline is not known. The primary objective of the proposed study is to determine the effects of an acute bout of strenuous endurance exercise on iron absorption and status and markers of inflammation in human volunteers. The investigators hypothesize that an acute bout of strenuous endurance exercise, compared to rest, will reduce iron absorption, resulting in diminished iron status, and that reduced iron absorption will be negatively associated with markers of inflammation. A secondary objective is to monitor iron status throughout a season of competition.


Eligibility criteria: Inclusion Criteria:

* Members of the Florida State University Cross Country team
* Refrain from using any pain-relievers (e.g., acetaminophen, nonsteroidal anti-inflammatory drugs such as aspirin, Advil®, Aleve®, Naprosyn®), or any other aspirin-containing product on the 2 study days
* Refrain from using vitamin or mineral supplements on the study days

Exclusion Criteria:

* Musculoskeletal injury that compromise the ability to exercise

Primary outcomes:
measure: Change in fractional iron absorption
timeFrame: Red blood cells collected on day 0 and day 14
Secondary outcomes:
measure: Change in concentration of ferritin in ng/mL
timeFrame: Day 0 and day 14
measure: Change in concentration of soluble transferrin receptor in nmol/L
timeFrame: Day 0 and day 14
measure: Change in concentration of hemoglobin in g/L
timeFrame: Day 0 and day 14
measure: Change in concentration of hematocrit as %
timeFrame: Day 0 and day 14
measure: Change in concentration of hepcidin in ng/mL
timeFrame: Day 0 and day 14
measure: Change in concentration of IL-6 in pg/mL
timeFrame: Day 0 and day 14
Other outcomes:
Locations:
city: Tallahassee
country: United States
facility: Florida State University
state: Florida
Study officials:
References:
citation: Barney DE, Ippolito JR, Berryman CE, Hennigar SR. A Prolonged Bout of Running Increases Hepcidin and Decreases Dietary Iron Absorption in Trained Female and Male Runners. J Nutr. 2022 Sep 6;152(9):2039-2047. doi: 10.1093/jn/nxac129.
Clinical trial NCT02958722: Comparison Between Two Different Distention Medium in Diagnostic Hysteroscopy
Official title: CO2 or Physiological Solution as Distension Medium: Which One is Better in Diagnostic Hysteroscopy?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hysteroscopy, Distension Medium, Pain
Lead sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Sponsor class: OTHER
First posted: 2016-11-08
Enrollment: 2000
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The investigators aim to enroll 2000 patients to undergo diagnostic hysteroscopy for suspected uterine pathologies. Women will be randomized into two groups on the basis of distension medium : group A CO2; group B physiological solution. Pain discomfort will be evaluated after the examination.


Eligibility criteria: Inclusion Criteria:

* suspected uterine pathologies
* infertility

Exclusion Criteria:

* pregnancy
* severe hypertension, cardiovascular disease or respiratory disease

Primary outcomes:
measure: pain discomfort during the procedure assessed through visual analogue scale (VAS)
timeFrame: up to six months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04562922: LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy
Official title: LIFEMEL Efficacy in Preventing Haematopoietic Toxicity in Patients Treated With Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Neutropenia
Adverse Event
Lead sponsor: VitalMel
Sponsor class: INDUSTRY
First posted: 2020-09-24
Enrollment: 39
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: LEO trial was designed to assess the benefit of administering LifeMel to prevent myelotoxicity in patients affected by solid neoplasm undergoing antiblastic chemotherapy treatment at low to moderate risk of febrile neutropenia. Secondary endpoints of LEO trial were assessing impact of LifeMel in preventing anaemia and thrombocytopenia.

Detailed description: The LEO trial was designed to assess the benefit of administering LifeMel, a honey from bees obtained using Zuf Globus Ltd technology, produced in Israel and listed by the Ministry of Health in Italy as a food supplement. This study aims to highlight a possible role of Lifemel in preventing neutropenic events, as well as reducing anaemia and thrombocytopenia following the administration of chemotherapy in patients with a histological or clinical diagnosis of solid neoplasia undergoing first-line chemotherapy.

Eligibility criteria: Inclusion Criteria:

* age \>=18 years old
* histological or clinical diagnosis of solid neoplasia
* indication for chemotherapy treatment with regimens at moderate risk of neutropenia fever - duration of chemotherapy treatment more than 3 months

Exclusion Criteria:

* known intolerances to honey containing compounds
* decompensated diabetes or severe glucose intolerance
* diseases or therapies significantly affecting the neutrophil count
* concurrent use of G-CSF as primary or secondary prophylaxis in the study

Primary outcomes:
measure: Neutropenia
timeFrame: Three months for each patient
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Department of Oncology, A.O.U. Maggiore della Carità, Novara, Italy.
name: Andrea Pietro Sponghini
role: PRINCIPAL_INVESTIGATOR
References:
citation: Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997 Feb;13(2):63-74. doi: 10.1016/s0885-3924(96)00274-6.
citation: Abdel-Razeq H, Hashem H. Recent update in the pathogenesis and treatment of chemotherapy and cancer induced anemia. Crit Rev Oncol Hematol. 2020 Jan;145:102837. doi: 10.1016/j.critrevonc.2019.102837. Epub 2019 Nov 26.
citation: Zidan J, Shetver L, Gershuny A, Abzah A, Tamam S, Stein M, Friedman E. Prevention of chemotherapy-induced neutropenia by special honey intake. Med Oncol. 2006;23(4):549-52. doi: 10.1385/MO:23:4:549.